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Abstract
Background: Traumatic spinal cord injury (SCI) results in partial or complete paralysis and is characterized by a loss of
neurons and oligodendrocytes, axonal injury, and demyelination/dysmyelination of spared axons. Approximately 1,250,000
individuals have chronic SCI in the U.S.; therefore treatment in the chronic stages is highly clinically relevant. Human neural
stem cells (hCNS-SCns) were prospectively isolated based on fluorescence-activated cell sorting for a CD133
+ and CD24
2/lo
population from fetal brain, grown as neurospheres, and lineage restricted to generate neurons, oligodendrocytes and
astrocytes. hCNS-SCns have recently been transplanted sub-acutely following spinal cord injury and found to promote
improved locomotor recovery. We tested the ability of hCNS-SCns transplanted 30 days post SCI to survive, differentiate,
migrate, and promote improved locomotor recovery.
Methods and Findings: hCNS-SCns were transplanted into immunodeficient NOD-scid mice 30 days post spinal cord
contusion injury. hCNS-SCns transplanted mice demonstrated significantly improved locomotor recovery compared to
vehicle controls using open field locomotor testing and CatWalk gait analysis. Transplanted hCNS-SCns exhibited long-term
engraftment, migration, limited proliferation, and differentiation predominantly to oligodendrocytes and neurons.
Astrocytic differentiation was rare and mice did not exhibit mechanical allodynia. Furthermore, differentiated hCNS-SCns
integrated with the host as demonstrated by co-localization of human cytoplasm with discrete staining for the paranodal
marker contactin-associated protein.
Conclusions: The results suggest that hCNS-SCns are capable of surviving, differentiating, and promoting improved
locomotor recovery when transplanted into an early chronic injury microenvironment. These data suggest that hCNS-SCns
transplantation has efficacy in an early chronic SCI setting and thus expands the ‘‘window of opportunity’’ for intervention.
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Introduction
Traumatic spinal cord injury (SCI) results in partial or
complete paralysis along with sensory loss below the level
ofinjury. The pathology of SCI is characterized by the loss of
neurons and oligodendrocytes, axonal injury, and demyelin-
ation/dysmyelination of spared axons. Therapeutic transplan-
tation of stem cell populations may promote functional recovery
by providing trophic support, modifying the host environment
to create a permissive environment for endogenous regenera-
tion/repair, or by replacing neurons and/or oligodendrocytes
[1,2].
SCI therapies can target acute, sub-acute, or chronic time
points post-injury. The continuum from acute to chronic injury
both in animal models and clinically is defined by the transition
from a dynamic to a relatively stable injury environment, and
when behavioral recovery reaches a plateau [3,4,5]. In rodent
contusion injury models these criteria are met beginning at
approximately 30 days post-injury (dpi) [3,4,5]. There are over
1,275,000 individuals living with chronic SCI in the U.S. alone
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Center); thus, a chronic transplantation model is highly clinically
relevant.
Several studies have investigated chronic SCI models using
whole tissue grafts and peripheral nervous system (PNS) cells.
Transplantation of fetal spinal tissue, fetal brain cortex, olfactory
ensheathing cells (OECs), peripheral nerve grafts, and Schwann
cells after SCI have all been shown to improve locomotor recovery
[6,7,8,9,10,11], suggesting that the chronic post-injury period may
be a feasible target for repair.
In contrast, the few studies that have compared sub-acute and
chronic transplantation of CNS cell populations such as human
oligodendrocyte progenitor cells (OPCs) and mouse neural stem
cells (NSCs) in chronic SCI models have not reported improved
locomotor recovery [12,13]. Human OPCs transplanted 7 dpi
survived and promoted locomotor recovery; however, at 10
months post-injury, OPCs survived but failed to improve
locomotor recovery [12]. Mouse NSCs transplanted 2 weeks
post-SCI survived and improved locomotor recovery; however, at
2 months post-SCI, NSCs neither survived nor improved
locomotor recovery [13].
Thus, while whole tissue grafts and PNS cells have shown some
capacity for chronic stage repair ($4 weeks post-SCI in rodents),
CNS cell populations have thus far failed in the chronic setting.
These studies suggest that the mechanism of cell transplant-
mediated repair, the properties of specific cell transplant
populations, and/or the microenvironment of the injured niche
during the acute, sub-acute, and chronic periods may influence the
potential to impact recovery post-SCI. Defining the potential
window for successful engraftment and recovery in animal models
with specific cell populations, particularly CNS populations, is
therefore a critical step to developing therapeutics for chronic
injuries.
We have previously reported that NOD-scid mice, which are
constitutively immunodeficient, lacking a normal T-cell, B-cell,
and complement response, exhibit similar SCI pathology and
cellular innate immune response to other mouse strains (C57Bl/6
and BUB/BnJ) [14]. Accordingly, NOD-scid mice provide an
excellent experimental model to investigate the potential of
transplanted human cell populations to engraft and promote
histological and locomotor recovery following SCI without a
xenograft rejection response [15]. Furthermore, NOD-scid mice
have been used as a host for induced pluripotent cells in the CNS
as an assay for tumor formation and NSC transplantation studies
[16,17]. Hence, stem cell transplantation in the CNS using the
NOD-scid model can provide tumorigenicity information. We
have previously reported on the sub-acute transplantation of
human neural stem cells (hCNS-SCns), which are lineage
restricted to generate neurons, oligodendrocytes, and astrocytes,
into a NOD-scid SCI model. hCNS-SCns are prospectively
isolated based on fluorescence-activated cell sorting (FACS) for a
CD133
+ and CD24
2/lo population from fetal brain and grown as
neurospheres [18].
hCNS-SCns transplanted sub-acutely 9 dpi in immunodeficient
NOD-scid mice successfully engrafted and improved long-term
locomotor recovery compared to vehicle and human fibroblast
(hFbs) control groups [19,20]. Notably, recovery was abolished
following selective ablation of hCNS-SCns using diphtheria toxin,
demonstrating that survival of hCNS-SCns was required to sustain
locomotor recovery [19]. The majority of hCNS-SCns exhibited
differentiation to oligodendrocytes, and a smaller percentage
differentiated into neurons, but few exhibited evidence of
astrocytic fate [19]. This is in contrast to many studies that have
demonstrated predominant astroglial fate or differentiation failure
following acute or sub-acute NSCs transplantation,
[21,22,23,24,25,26,27]. Furthermore, immuno-electron microsco-
py in the sub-acute study revealed that human cells remyelinated
mouse host axons and formed putative synapses with mouse
neurons, suggesting that transplanted hCNS-SCns had stably
integrated within the functional cytoarchitecture of the host CNS
[19].
In the present study, we tested whether hCNS-SCns trans-
planted into immunodeficient NOD-scid mice at an early chronic
time point (30 dpi), survived, differentiated, and promoted
locomotor recovery. We also investigated whether the animals
experienced mechanical allodynia, and stereologically quantified
the number of engrafted cells, lesion volume, spared tissue volume,
and glial scar area. Our results reveal that hCNS-SCns have the
ability to survive, migrate, differentiate, and promote improved




All animal housing conditions, surgical procedures, and
postoperative care was approved by and conducted according to
the Institutional Animal Care and Use Committee (IACUC)
guidelines at the University of California, Irvine. The UC Irvine
Human Stem Cell Research Oversight Committee (UCI hSCRO)
approved the use of human stem cells in this study.
Group design
Female mice were used in this study to avoid bladder
complications and urolithiasis that frequently occur in male mice
following SCI [14,28]. Animal surgeries were done in parallel over
multiple days. Prior to surgery, NOD-scid mice (n=48) were tested
by the Basso Mouse Scale (BMS) to ensure normal locomotor
function. One animal was excluded at this time because of
abnormal gait. During the initial SCI surgery, one animal died
and three additional animals were excluded because of surgical
error. Pre-hoc criteria were established to exclude animals if any of
the following conditions occurred: cord bruised or tearing of dura
during laminectomy (n=1); visual slippage of the mouse from the
vertebral stabilization clamps (n=0); abnormal time versus force
curve indicating a bone hit or clamp slip (n=1); or unilateral
bruising of the cord (n=1). Mice (n=44) received BMS testing
2 dpi and weekly thereafter and were randomized into 3 balanced
groups, to be transplanted with either vehicle control, hFbs, or
hCNS-SCns, based upon their BMS scores at 28 dpi. To minimize
the effect of variations in spinal cord damage, seven animals were
excluded prior to transplantation because their BMS scores at
28 dpi were more than two standard deviations from the mean
score. Thirty-seven mice were transplanted 30 dpi. Slightly more
animals were included in the hCNS-SCns group for purposes of
histological analysis; vehicle control (n=11), hFbs (n=11), and
hCNS-SCns (n=15). Following transplantation, four animals died
prior to sacrifice, one from the vehicle group, two from the hFbs
group, and one from the hCNS-SCns group. The final animal
numbers per group were, vehicle (n=10), hFbs (n=9), and hCNS-
SCns (n=14).
Spinal Cord Injury
Female NOD-scid mice (transferred from StemCells Inc, the
Jackson Laboratory, stock # 001303), 8–10 weeks of age were
anesthetized with tribromoethanol (312.5 mg/kg i.p. bolus) and
vertebral T9 exposed by laminectomy as previously described
[29]. Mice received a 50-kDyne-contusion injury using the IH
hCNS-SCns in Early Chronic SCI
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surgery, mice recovered overnight in cages with Alpha-Dri
bedding (Newco Distributors Inc) placed on water-jacketed
heating pads at 37uC. Mice were maintained on twice daily
manual bladder expression for 2 weeks, followed by once daily
manual bladder expression for the remaining survival period. Post-
operative care included buprenorphine twice a day for 2 days,
lactated ringers once a day for 4 days, and antibiotic daily for the
duration of the study. All animals were maintained on rotating
schedule of antibiotics; Baytril, Amoxicillin, and Cipro were each
given for 2 weeks, and then rotated to the next antibiotic.
Transplantation surgery
Isolation and culture of hCNS-SCns from fetal brain tissue
(gestational 16–20 weeks) have been previously described
[18,19,30]. Briefly, FACS-sorted single cell suspensions were
cultured in neurosphere initiation media consisting of Ex-Vivo 15
media with N2 supplement, FGF, EGF, LIF, neural survival factor-
1, and NAC. Cells were propagated as neurospheres, fed weekly,
and passaged every 2–3 weeks [18,19,30]. Human fibroblasts
derived from fetal liver were grown to confluence in Iscove’s
modified Dulbecco’s medium/10% FBS, dissociated with trypsin,
washed and concentrated to 50,000 cells per ml. Thirty days post-
injury, mice were anesthetized with tribromoethanol (312.5 mg/kg
i.p. bolus), the laminectomy site re-exposed and hCNS-SCns or
hFbs were transplanted. Four injections of 250 nl each, bilateral
from the midline, both rostral and caudal to the injury epicenter
were performed using a beveled glass (0.53 mm I.D, 1.14 mm O.D.
Drummond Scientific Co.) micropipette (75–80 mm ID, 100–
115 mm, 30u bevel Sutter Instrument Co.) and NanoInjector 2000
system (World Precision Instruments) delivering a total of 1 mlo f
hCNS-SCns at 75,000-cells/ml, or hFbs at 50,000-cells/mli na n
injection buffer consisting of 50% Hanks’ balanced salt solution and
50% X-vivomedium. Vehicle control mice received injection buffer
alone. Mice received post-operative treatment as described above.
BMS
Open-field locomotor recovery was assessed using the BMS
locomotor rating scale prior to injury, 2 days after injury, weekly for
4 weeks until transplantation, then weekly following transplantation
until sacrifice. Briefly, mice were observed in the open-field for 4
minutes each by two individuals blinded to the experimental groups
[31,32]. Motor function of the hind limbs was rated, recorded, and
converted to a score according to the published scale.
CatWalk Analysis
CatWalk video was recorded at 16 weeks post-transplantation.
Individuals blinded to experimental groups analyzed video using
CatWalk software version 6.13 for Windows [33].
Mechanical Allodynia
Von Frey hair testing of hind limbs was done at 15 weeks post-
transplantation. Animals were tested for a withdrawal response to
successively higher force filaments (Touch-Test Sensory Evalua-
tors, North Coast Medical). The lowest filament from which an
animal withdrew from was the threshold assigned for that animal
[34]. After a positive response was elicited, the previous filament
was tested to confirm a lack of response and the next filament was
tested to confirm a positive response.
Histological Assessment
Sixteen weeks post-transplantation, mice were anesthetized using
pentobarbital (100 mg/kg) and transcardially perfused with 15 mls
of PBS followed by 100 mls of 4% phosphate-buffered paraformal-
dehyde. A T6-T12 segment of the spinal cord was dissected based
on counting the dorsal spinal roots for all mice to obtain an
anatomically consistent region of the spinal cord for stereological
analysis. Spinal roots were identified by visualization of the features
of C6, C7 and C8 root brachial plexus and exposure of the distal
thoracic roots. Dissected T6-T12 spinal cord segments were post-
fixed in a 20% sucrose/4% paraformaldehyde solution for
cryoprotection overnight at 4uC. Following cryoprotection, spinal
cords were frozen in isopentane at 265uC, and serial sliding
microtome sections were collected free floating for immunocyto-
chemical staining. Parasagittal sections (n=6 per group) were
collected at 30 mm for human cytoplasm and paranodal protein
(CASPR) double immunofluorescence and stereological analysis of
hCNS-SCns and hFbs survival and migration, lesion volume,
spared tissue volume,and glial scar area. Coronal sections (n=3 per
group) were collected at 50 mm for fate analysis. Immunocyto-
chemistry was conducted as previously described [35] sampling
throughout the T6–T12 segment of the spinal cord using anti-
human cytoplasm marker (SC121-StemCells, Inc 1:4000), anti-
GFAP marker (GFAP-Dako 1:60,000), anti-human GFAP marker
(SC123-StemCells,Inc 1:3000) and visualized using diaminobenzi-
dine (DAB; Vector Laboratories). For fluorescent labeling we
utilized anti-human cytoplasm marker (SC121-StemCells, Inc
1:4000), anti-human nuclei marker (SC101- StemCells, Inc
1:100), anti-human nuclei marker (Millipore 1:200), anti-APC-
CC1 marker (Calbiochem 1:4000), anti-human Olig2 (R&D
Systems 1:100), anti-ß-tubulin-III (Convance 1:5000), anti-GFAP
(Dako 1:30,000), anti-Nestin (Covance 1:1000), anti-Ki67 (Novo-
castra 1:1500), and anti-CASPR (Abcam 1:500). Secondary
antibodies in double-labeling experiments were Alexa Fluor 488
and 555 (Molecular Probes 1:500). Fluorescent sections were
mounted with Vectashield mounting medium for fluorescence with
DAPI (Vector Laboratories).
Stereological Quantification
Stereology was conducted using an Olympus BX51 microscope
with a motorized stage and StereoInvestigator software (MBF
Biosciences, version 7.00.3). Survival of human cells, hCNS-SCns
(n=6) and hFbs (n=5), was quantified by SC121 immunolabeling
and methyl green nuclear counterstainusing the optical fractionator
probe and a 1006oil-immersion 1.30 numerical aperture objective.
Human cells were quantified in the injury epicenter, spared tissue
and sequential 1 mm segments rostral and caudal to the injury site.
Systematic random sampling of the tissue was performed according
to stereological principles. Starting sections were chosen at random
and every sixth section thereafter was analyzed. Sampling
parameters (grid and counting frame size) were empirically
determined to achieve low coefficients of error (CE) for each
measure. CE values are summarized in Table 1. Lesion volume,
spared tissue volume, and glial scar area were quantified using
GFAP staining and the Cavalieri probe at 46in all three groups
using parasagittal sections, vehicle (n=5), hFbs (n=5), and hCNS-
SCns (n=6). Lesion volume was quantified as the area at the injury
epicenter that was devoid of GFAP staining using a 100 mm grid.
Spared tissue volume was quantified in 500 mm segments rostral
and caudal of the injury epicenter using a 100 mm grid. Glial scar
area was quantified by measuring the area of dense GFAP staining
near the injury epicenter and excluding the lesion as defined by
absence of GFAP staining using a 150 mm grid.
Quantification of human cell differentiation
hCNS-SCns differentiation was examined by double fluorescent
labeling. Confocal imaging of fluorescent stained sections was
hCNS-SCns in Early Chronic SCI
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LSM 510 software (Version 4.0 SP2) with multi-track scanning.
Three animals for each protein marker were utilized. For
quantification of each protein marker, starting sections were
chosen at random and every twelfth coronal section thereafter was
stained. From the 1 in 12 sampling of sections stained, the ten
consecutive sections that contained the most human cells were
utilized for fate analysis. In each of the ten consecutive sections,
ten fields were imaged using a 636objective and 26digital zoom.
The number of human cells, and double-labeled cells were
counted for each series using ImageJ Version 10.2 software with a
cell counter plug-in. The number of double-labeled cells is
expressed as a percentage of the total number of human cells
counted in each individual series. For each protein marker
analyzed, the values from three animals are averaged together to
get the final percentage.
Statistical Analysis
All means are expressed 6 the standard error of the mean. For
BMS, repeated measures ANOVA was used to compare scores of
vehicle, hFbs, and hCNS-SCns transplanted animals. For BMS,
linear single degree of freedom contrast statistics and a
Bonferroni/Dunn post-hoc analysis was utilized to determine
significance at the termination of the study (week 16). Chi-square
analysis was utilized to assess the observed frequency of animals
recovering coordination in the open field with a Fisher’s exact test.
CatWalk gait analysis of swing speed was analyzed with a one-way
ANOVA and Fisher’s PLSD post-hoc test. A one-way ANOVA
was used to assess von Frey, lesion volume, spared tissue volume,
and glial scar area for differences between the three groups.
StatView (version 5.0.1) and Prism (version 5.0a) were used for
statistical analysis; significance was defined as p#0.05.
Results
hCNS-SCns promote locomotor recovery
To investigate whether hCNS-SCns can contribute to long-term
locomotor recovery in an early chronic SCI model mice received
grafts of hCNS-SCns, hFbs, or a vehicle control injection 30 days
post contusion injury. All mice were pre-tested for baseline
locomotor performance using the BMS prior to SCI and any
animals with locomotor deficits were excluded prior to injury
(Fig. 1A). After SCI, mice were tested at 2, 7, 14, 21, and 28 dpi,
and then weekly following transplantation until sacrifice. Prior to
transplantation, mice were randomized into 3 groups based upon
BMS scores at 28 dpi, so that each group started with a similar
score as described under methods. hCNS-SCns transplanted mice
exhibited significantly improved locomotor recovery compared to
vehicle control mice; repeated measures ANOVA p#0.0022
(F=1.952), Bonferroni/Dunn posthoc analysis at week 16
p#0.02. There were no significant differences in repeated
measures ANOVA between hFbs and either the hCNS-SCns or
vehicle control groups. BMS scores were further analyzed using a
test of the interaction of the groups across time following
transplantation, which was significant (p=0.002), indicating that
the group means changed differently over time. To further
characterize what the changes across time were, a linear contrast
of the interaction term was determined and was found to be highly
significant (p,0.0001), indicating that the groups made linear
changes across time with different slopes. Finally, the slope of each
group was investigated individually. Based on adjustments for
multiple testing, the p-value required to reach significance in this
analysis was p#0.0167. While the vehicle group exhibited a non-
significant trend for a linear decrease in means over time
(p=0.023) and the hFbs group exhibited no linear change in
means over time (p=0.115), the hCNS-SCns exhibited a
significant linear increase in means over time (p=0.001)
suggesting that only hCNS-SCns treated animals had significantly
improved recovery over the 16 weeks following transplantation. At
16 weeks post-transplant (termination of the study) the average
BMS scores per group were: hCNS-SCns (n=14) 6.460.4; hFbs
(n=9) 5.660.6; and vehicle treated animals (n=10) 4.860.5.
These scores correspond to improvement in the frequency of
coordinated steps between fore and hind limbs for hCNS-SCns vs.
vehicle groups.
Because BMS scores showed differences in the recovery of
coordination between groups, we used chi square frequency
analysis to compare the number of animals in each group that had
regained at least occasional coordination between fore and hind
limbs on open-field behavior testing. Data is expressed as the
percentage of animals that exhibited coordination between fore
and hind limbs out of the total number of animals per group
(Fig. 1B). 64% of hCNS-SCns mice recovered coordination
compared to 44% for hFbs mice and 20% for vehicle control
mice. Recovery of coordination was significantly increased in
hCNS-SCns transplanted animals compared to vehicle controls
using chi square analysis for observed frequency (p=0.047,
Fisher’s Exact Test). No statistically significant differences were
found comparing hFbs with either vehicle or hCNS-SCns
transplanted mice.
As a supplemental quantitative measure of locomotor recovery,
CatWalk gait analysis was performed in a subset of animals at 16
weeks post-transplant prior to sacrifice. CatWalk gait analysis
showed that hCNS-SCns treated animals (n=10) had significantly
improved swing speed 1.21 m/s60.06 compared to vehicle
controls (n=8) 1.05 m/s60.06 (p,0.04 ANOVA, Fisher’s PLSD)
(Fig. 1C). However, hFbs treated mice (n=8) 1.13 m/s60.04 did
not exhibit significant differences from either vehicle control or
hCNS-SCns treated mice. Taken together, these data suggest that
hCNS-SCns were able to promote improved behavioral recovery
following early chronic transplantation.
hCNS-SCns do not contribute to allodynia
Recent studies have suggested that predominant astrocytic
differentiation of transplanted NSCs is associated with the
development of allodynia [21,36], defined as increased sensitivity
to stimuli that are normally not noxious, whether improved
locomotor recovery was observed or not. In one study [36],
Table 1. Intra-animal variability in stereological analyses.
Parameter of Analysis
hCNS-SCns/hFbs Number Lesion Volume Spared Tissue GFAP Scar
Mean Coefficient of Error (CE) ,0.0580/,1 per region 0.0466 0.0295 0.0334
doi:10.1371/journal.pone.0012272.t001
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into astrocytes. We assessed hind limb mechanical allodynia 15
weeks post-transplant to determine the lowest threshold force from
which animals withdrew their paw. Vehicle treated animals
exhibited a threshold of 6.0 g61.0 (n=9), hFbs 6.0 g60.5 (n=9),
and hCNS-SCns treated animals 6.4 g61.4 (n=10) (Fig. 1D).
None of the groups were significantly different from one another
by one-way ANOVA (p$0.94), suggesting that hCNS-SCns
treated animals did not have an altered threshold of response to
mechanical allodynia as a result of hCNS-SCns transplantation.
hCNS-SCns survive, engraft, and migrate within the
injured spinal cord
To investigate the survival and migration of transplanted cells,
mice were sacrificed 16 weeks post-transplantation and engrafted
human cells detected using an antibody to human cytoplasm
(SC121) (Fig. 2A–E). All transplanted animals exhibited successful
human cell engraftment. There were no human cells present in
vehicle treated animals and relatively few engrafted hFbs in hFbs
transplanted animals, but numerous engrafted hCNS-SCns
(Fig. 2A–C). hCNS-SCns were found in both gray and white
matter, and the cells were morphologically distinct across these
regions. Cells found in the white matter had elongated
oligodendrocyte-like morphology (Fig. 2D), while those in the
gray matter exhibited neuronal morphologies (Fig. 2E). Engrafted
cells were distributed throughout gray and white matter of the
cord with no evidence of abnormal morphology or any mass
formation indicative of tumorigenesis.
The number of surviving cells was quantified stereologically
using the optical fractionator probe. The initial transplant
contained 75,000 hCNS-SCns per animal; stereological estimates
of hCNS-SCns (n=6) revealed an average of 215,711648,978
hCNS-SCns present 16 weeks following transplantation (Fig. 2F).
These values represent an approximately 3-fold increase in the
initial cell population transplanted. The initial hFbs transplant
contained 50,000 cells; stereological estimates of hFbs engraftment
Figure 1. hCNS-SCns promote improved locomotor recovery on multiple tests. (A) BMS locomotor performance is significantly improved in
hCNS-SCns treated animals compared to vehicle controls (repeated measures ANOVA (p#0.0022). A Bonferroni/Dunn post-hoc analysis at week 16
revealed a significant difference between hCNS-SCns and vehicle control (p#0.02). There were no significant differences between hFbs and either
hCNS-SCns or vehicle. (B) Recovery of coordination was significantly increased in hCNS-SCns treated animals compared to vehicle controls using chi
square analysis for observed frequency (p#0.047, Fisher’s Exact Test). No statistically significant differences were found comparing hFbs with vehicle
or hCNS-SCns transplanted animals. Error bars are not plotted as these bars represent the absolute percentage of animals reaching criteria. (C)
CatWalk gait analysis showed that hCNS-SCns treated animals exhibited significantly increased swing speed compared to vehicle treated animals
(p#0.04, ANOVA, Fisher’s PLSD). (D) von Frey analysis of mechanical allodynia showed no significant differences between any of the groups (p.0.05
ANOVA).
doi:10.1371/journal.pone.0012272.g001
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following transplantation (Fig. 2F). These values represent a near
4-fold decrease of the initial cell population transplanted and
suggest that hFbs did not survive well, nor did they proliferate.
During the sub-acute period a glial scar forms that includes
growth inhibitory chondroitin-sulfate proteglycans (CSPGs)
[37,38,39]. The properties of the glial scar and CSPGs contribute
to an environment that is inhibitory to axonal regeneration and
neurite outgrowth and has been suggested to prevent migration of
transplanted cell populations [40,41]. We have previously
demonstrated glial scar formation and CSPG deposition (NG2
and Versican) in NOD-scid mice following SCI suggesting the
Figure 2. Transplanted hFbs survive and hCNS-SCns survive and migrate extensively. Histology of spinal cords stained for human
cytoplasm (SC121, brown and methyl green nuclear counterstain, blue) 16 weeks post-transplantation (A) reveal no human cells in vehicle treated
animals, (B) few human cells in hFbs treated animals, and (C) many human cells surviving and migrating the length of the cord in hCNS-SCns treated
animals. hCNS-SCns exhibit distinct morphologies in white vs. gray matter. (D) In white matter hCNS-SCns exhibit oligodendrocyte-like morphology.
(E) In gray matter hCNS-SCns exhibit neuronal morphology Scale bar on left: 1000 mm. Scale bar on right: 50 mm. (F) 50,000 hFbs were initially
transplanted (red line) and 11,70163070 remain at the termination of the study. 75,000 hCNS-SCns were initially transplanted (blue line) and
215,711648,978 were present at the termination of the study as estimated using unbiased stereological quantification. (G) Unbiased stereological
quantification was used to assess the migration of transplanted cells in 1 mm blocks extending 8 mm rostral and caudal from the injury site including
the spared tissue (s.t., vertical dashed line) surrounding the lesion. hCNS-SCns migrated up to 8 mm rostral and 5 mm caudal (left y-axis, blue). hFbs
migrated 2 mm rostral and 2 mm caudal (right y-axis, red).
doi:10.1371/journal.pone.0012272.g002
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environment to transplanted hCNS-SCns [30]. Accordingly, we
investigated whether migration of hCNS-SCns and hFbs occurred
following transplantation in the early chronic injury environment
in which the glial scar and associated CSPGs are present.
Migration of both hCNS-SCns and hFbs was assessed within the
root dissected injury segments of the cord (T6–T12) that extends
approximately 8 mm rostral and 5 mm caudal from the injury
epicenter, including the spared tissue around the injury epicenter
(vertical dashed line, Fig. 2G). The spared tissue area was defined
as the intact region of cord surrounding the methyl green positive
dense lesion core. We also quantified surviving cells within the
lesion core, which both hCNS-SCns and hFbs tended to avoid. In
this region, we counted only 572861317 hCNS-SCns and
3036169 hFbs, mostly localized to the lesion rim and rarely
localized in the histological epicenter (Fig. 2G). hCNS-SCns
migrated much further than hFbs, up to 8 mm rostral and 5 mm
caudal compared to 2 mm rostral and 2 mm caudal for hFbs
(Fig. 2G). At the distal rostral segments there were an average of
384 and 697 hCNS-SCns at 8 and 7 mm, respectively and at the
distal caudal segments 1019 and 244 hCNS-SCns on average at 4
and 5 mm respectively. hCNS-SCns were concentrated in the
spared tissue area and up to 4 mm rostral to the injury and 2 mm
caudal. Similarly, hFbs were concentrated in the spared tissue area
and up to 2 mm rostral to the injury, but hFbs did not migrate any
further in the rostral direction and few cells were found in the
region up to 2 mm caudal to the injury. The furthest rostral
segments that hFbs migrated to contained an average of 3039 and
5769 hFbs at 5 and 4 mm, respectively and at the most caudal
segment there were an average of 423 and 357 hFbs at 1 and
2 mm respectively. Both cell populations were more prominent
rostral to the injury rather than caudal. Quantification revealed
robust engraftment and migration of hCNS-SCns transplanted
into an early chronic model of SCI.
hCNS-SCns differentiate into all 3 CNS cell types
To investigate how the early chronic injured environment
influenced the cell fate of engrafted hCNS-SCns, we assessed the
fate and differentiation of hCNS-SCns by double immunofluores-
cence and confocal analysis in a subset of hCNS-SCns transplant-
ed animals that were sectioned coronally. We investigated whether
hCNS-SCns exhibited active cell division/proliferation by double
labeling for SC121 and Ki67 and observed occasional co-
localization (Fig. 3A–E). To determine whether any hCNS-SCns
retained an immature phenotype we double labeled with SC121
and nestin and observed many co-localized cells (Fig. 3F–J). We
next sought to determine whether engrafted human cells
differentiated along oligodendroglial, neuronal, or astrocytic
lineages. We investigated both immature and mature oligoden-
drocyte differentiation by double labeling for human nuclei and
Olig2 to assess differentiation to immature oligodendrocytes
(Fig. 4A–E) and APC-CC1 to examine mature oligodendrocytes
(Fig. 4F–J). We observed hCNS-SCns double-labeled for both
oligodendroglial markers. SC121-positive cells also co-localized
with the neuronal marker b-tubulin III neurons suggesting hCNS-
SCns differentiated into neurons (Fig. 4K–O). Few SC121
immunopositive cells co-localized with GFAP suggesting rare
astrocytic differentiation (Fig. 4P–T).
We investigated the percentage of human cells that exhibited
evidence of active cell division/proliferation by double labeling for
SC121 and Ki67. 2.9%61.06 of SC121 positive human cells
exhibited double labeling for Ki67 (Fig. 5), suggesting that there is
limited proliferation of hCNS-SCns 16 weeks post-transplantation.
Double labeling of SC121 and nestin revealed 31.1%63.23 of
Figure 3. hCNS-SCns express Ki67 and nestin 16 weeks
following transplantation. (A–E) Human cytoplasm-positive cells,
(SC121), red (B) were rarely associated with the cell cycle marker Ki67,
green (C), DAPI counterstain, blue (A). Arrows indicate a double-labeled
cell. Merged confocal image, showing rare hCNS-SCns expression of
Ki67 indicating low mitotic activity (D). Orthogonal view of confocal
image showing co-localization of Ki67 and SC121 (E). (F–J) Some SC121
positive human cells, red (G) expressed the immature neural marker
hCNS-SCns in Early Chronic SCI
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many human cells at 16 weeks post-transplantation remain
immature (Fig. 5).
We next sought to determine the percentage of engrafted
human cells that differentiated along oligodendroglial, neuronal,
or astrocytic lineages. Quantification revealed 34.4%66.38
exhibited differentiation along the more immature Olig2-positive
oligodendrocyte lineage and 13.8%61.0 of human cells differen-
tiated into mature APC-CC1 positive oligodendrocytes (Fig. 5).
Together, differentiation along an oligodendrocyte lineage com-
prised 40.78% of the human cells, which was the predominant fate
of transplanted hCNS-SCns. 38.1%60.85 of SC121-positive cells
differentiated into b-tubulin III neurons, suggesting nearly as
many hCNS-SCns differentiated into neurons as oligodendrocytes
(Fig. 5). Few SC121 immunopositive cells differentiated into GFAP
positive astrocytes, 8.0%61.0 (Fig. 5).
Human myelinated host axons co-localize with contactin-
associated protein
hCNS-SCns in the white matter exhibited predominant
oligodendrocyte differentiation while ß-tubulin III co-localization
with SC121 was predominantly found within the gray matter and
processes rarely extended to the white matter. We previously
reported evidence that sub-acutely transplanted hCNS-SCns
remyelinated host axons, we sought to determine whether we
could visualize integration of human oligodendrocytes with the
host within white matter [19]. CASPR is highly localized to the
paranodal region of myelinated axons and can be used as an index
of myelin integrity [42,43,44]; previous studies have demonstrated
that CASPR has a compact paranodal restricted staining pattern
in uninjured axons (Fig. 6A arrows) and this compact pattern
becomes more diffusely distributed along the axon following SCI
(Fig. 6A arrowheads) [43]. To visualize human myelinated host
axons, we performed double immunofluorescence and confocal
analysis for the human cytoplasmic marker SC121 (red) and
CASPR (green) on parasagittal spinal cord sections 16 weeks
following transplantation (Fig. 6). Staining revealed human
myelinated host axons co-localized with compact CASPR in the
white matter expressing paranodal proteins in the correct loci,
suggesting hCNS-SCns integrated with the host.
hCNS-SCns do not affect lesion volume, spared tissue
volume, or glial scar area
While the presumptive strategy behind transplantation of stem
cell populations for SCI has been cell replacement via integration as
myelinating cells or new neurons, it is increasingly clear that
transplanted cells can have a variety of effects on the host
microenvironment including axonal regeneration and white matter
sparing [9,27,45,46,47,48,49,50]. To investigate the potential
effects of early chronic transplantation on host parameters we
assessed lesion volume, spared tissue volume, and glial scar area
using methodology that we have previously employed that detected
differences between complement knockout and wild type mice [28].
We have previously shown that hCNS-SCns transplantation 9 dpi
did not alter host parameters of injury or repair [30]. We
investigated host parameters of injury histologically by staining for
the glial scar marker GFAP (Fig. 7A). Furthermore, using an
antibody specific to human-GFAP (SC123) we investigated whether
humanastrocytescontributedtothehostlesionorglialscar(Fig.7B).
The few human-GFAP cells observed were primarily localized near
the injury epicenter (Fig. 7B). In the present study, lesion volume
was quantified stereologically using the Cavalieri estimator probe in
tissue stained for GFAP and counterstained with methyl green
(Fig. 7A). Lesion volume was defined as the methyl green dense area
devoid of GFAP staining (Fig. 7A), depicted with a blue outline.
Vehicle treated animals had an average lesion volume of
0.18 mm
360.06 (n=5), hFbs treated animals 0.16 mm
360.03
(n=5), and hCNS-SCns treated animals 0.19 mm
360.05 (n=6).
One-way ANOVA (p$0.91) revealed no significant difference
between any of the groups (Fig. 7C). We also quantified spared
tissue, defined by 500 mm segments both rostral and caudal of the
injury epicenter, excluding the lesion itself using Cavalieri estimator
probe, (Fig. 7A gray box). Vehicle treated animals had an average
spared tissue volume of 0.77 mm
360.11 (n=5), hFbs treated
animals 0.99 mm
360.05 (n=5), and hCNS-SCns treated animals
1.00 mm
360.11 (n=6). There were no significant differences
between any of the groups, one-way ANOVA (p$0.21) (Fig. 7D).
Glial scar area, defined as the dense GFAP staining surrounding the
injury epicenter excluding the lesion core, depicted with a black
outline, (Fig. 7A) was quantified stereologically using the Cavalieri
estimator probe in all three groups to determine whether hCNS-
SCns contributed to the glial scar (Fig. 7E). Vehicle treated animals
had an average glial scar area of 4.11 mm
260.80 (n=5), hFbs
treated animals 4.19 mm
261.00 (n=5), and hCNS-SCns treated
animals 4.32 mm
260.67 (n=6). There were no significant
differences in glial scar area between any of the groups (one-way
ANOVA p$0.98) suggesting that hCNS-SCns treatment neither
exacerbated nor reduced the glial scar (Fig. 7E). Taken together,
these data suggest that hCNS-SCns do not influence the lesion or
spared tissue volumes, or glial scar area. We also assessed whether
there were any correlations between lesion volume, spared tissue
volume, or glial scar area with the number of engrafted hCNS-
SCns. There were no significant correlations for any of these
comparisons (data not shown).
Discussion
hCNS-SCns promote locomotor recovery
Our findings reveal hCNS-SCns transplanted into early chronic
spinal cord injured NOD-scid mice survived, proliferated, and
differentiated primarily into oligodendrocytes and neurons. This is
the first study, to our knowledge, transplanting NSCs into early
chronic SCI in which observed improved behavioral recovery has
been detected. We assessed behavior via open-field locomotor
testing (BMS) and CatWalk gait analysis. Our results showed
improved recovery on BMS that was specifically enhanced in the
range of coordination; hCNS-SCns treated mice exhibited a
greater frequency of coordination compared to vehicle treated
animals. Additionally, hCNS-SCns treated animals demonstrated
improved swing speed compared to vehicle controls. hCNS-SCns
transplantation did not result in detectable hind limb allodynia.
Furthermore, transplanted hCNS-SCns had no measurable effect
on lesion volume, spared tissue volume, or glial scar area. Taken
together, these data suggest that stem cell transplantation can be
successful outside the sub-acute time window and may be a
potential therapeutic strategy for SCI at more chronic time points
than commonly predicted.
Human fibroblasts as a cellular control
In addition to a vehicle control we also utilized human
fibroblasts as a cellular control in this study to assess whether
nestin, green (H) DAPI counterstain, blue (F). Arrows indicate a double-
labeled cell. Merged confocal image reveals many hCNS-SCns maintain
immature phenotypes and nestin expression 16 weeks after transplan-
tation (I). Orthogonal view of confocal image revealing co-localization
of nestin and SC121 (J). Scale bars =20 mm and 10 mm in the bottom
row.
doi:10.1371/journal.pone.0012272.g003
hCNS-SCns in Early Chronic SCI
PLoS ONE | www.plosone.org 8 August 2010 | Volume 5 | Issue 8 | e12272Figure 4. hCNS-SCns mostly differentiate into oligodendrocytes and neurons, and few astrocytes. (A–E) Several human nuclei positive
cells, green (C), expressed Olig2 marker revealing immature oligodendrocytes, red (B), DAPI counterstain, blue (A). Arrows indicate a double-labeled
cell. Merged confocal image, showing hCNS-SCns expression of Olig2 indicating differentiation to oligodendrocytes (D). Orthogonal view of confocal
image showing co-localization of Olig2 and SC101 (E). (F–J) Some human nuclei-positive cells, SC101 green (H) also express the mature
oligodendrocyte marker APC-CC1, red (G), DAPI counterstain, blue (F) Arrows indicate a double-labeled cell. Merged confocal image reveals some
hCNS-SCns express APC-CC1 expression 16 weeks after transplantation. (I). Orthogonal view of confocal image revealing co-localization of APC-CC1
hCNS-SCns in Early Chronic SCI
PLoS ONE | www.plosone.org 9 August 2010 | Volume 5 | Issue 8 | e12272the integration and differentiation of hCNS-SCns promotes
improved recovery or whether any transplanted cell might affect
behavioral recovery in either a detrimental or beneficial manner.
Transplanted hFbs survived in all animals, but showed poor
engraftment, with fewer than 25% of the initial transplanted
population surviving 16 weeks later. Furthermore, hFbs did not
migrate far, remaining near transplant sites. As we previously
observed in a sub-acute transplant paradigm transplanting both
hCNS-SCns and hFbs, animals receiving hFbs were intermediate
in locomotor recovery between vehicle controls and hCNS-SCns
transplanted animals, albeit non-significantly [19]. Taken together
with the present study, the consistency of this finding suggests that
hFbs do exert some effect on the injured spinal cord. hFbs could
potentially improve locomotor recovery by secreting trophic
factors that provide support to the injured cord. While it is clear
there was limited survival and migration of hFbs, the data in this
study cannot distinguish whether hFbs exhibited poor survival
post-transplantation, or poor engraftment over time in the injured
microenvironment. Perhaps greater engraftment of hFbs could
also produce recovery of locomotor function following SCI, if it
could be achieved. However, the lack of robust survival or
proliferation of this cell population when transplanted into the
parenchyma adjacent to the SCI epicenter, even in the absence of
xenograft rejection suggests that this may not be possible.
hCNS-SCns successfully engraft and migrate
Successful engraftment in CNS transplantation studies is very
difficult to achieve, especially for xenografts. Currently, little is
known about the dynamics of stem cell survival, proliferation, and
migration in the SCI microenvironment because few studies have
assessed these parameters. Furthermore, many studies fail to
achieve adequate control of host immunorejection, making the
assessment of these parameters very difficult. For stem cells to
engraft in a therapeutically meaningful way, they need to survive
both the initial transplantation and host-mediated rejection. The
few studies that have quantified engraftment, in immunosup-
pressed xenograft or allograft models, as an endpoint report
between 0.1% to 37% of the initial transplanted cells detected at
time of sacrifice [6,13,36,51,52,53,54,55,56]. Additionally, few
studies report the percentage of transplanted animals that are
engrafted at the termination of the study, but under standard
immunosuppression methods this is often as low as 50–60% in
CNS injury models [57]. Because many studies fail to achieve
successful engraftment this may explain why there has yet to be a
successful report of NSCs improving recovery in a delayed
transplant paradigm.
In contrast, constitutively immunodeficient animals yield better
engraftment success, a study transplanting human NSCs into
athymic nude rats quantified 275% more cells than initially
transplanted [58]. Our studies have used NOD-scid mice, which
are constitutively immunodeficient, lacking a normal T-cell, B-cell,
and complement response. We have recently published a
characterization of lesion volume, the innate immune response,
and locomotor recovery in male and female NOD-scid mice in
comparison with C57Bl/6 and BUB/BnJ mice [14], and report
that NOD-scid mice do not exhibit differences in lesion
characteristics and are within the range of strain variation for
both macrophage and neutrophil responses. Therefore, despite the
congenital deficiency in the adaptive immune response the cellular
innate immune system is intact. While these mice also exhibit a
partial complement deficiency (C5), this is true for most other
mouse strains, including C57/Bl6, with the exception of BUB/
BnJs [28]. Furthermore, NOD-scid mice have been used as a host
for induced pluripotent cells in the CNS as an assay for tumor
formation as well as NSC transplantation [16,17]. Tumor
formation is much more likely to occur in the absence of a
rejection response therefore, NOD-scid mice allow for detection of
tumor formation or abnormal growth of transplanted stem cell
populations. However, one disadvantage of using NOD-scid mice
is that due to the rate of spontaneous fatal thymoma formation the
average lifespan of NOD-scid mice is roughly 8.5 months (34
weeks) limiting the length of studies that can be performed [59,60].
Accordingly, NOD-scid mice provide an excellent experimental
model to investigate the potential of transplanted human cell
populations to engraft and promote histological and locomotor
recovery following SCI without a xenograft rejection response
[15]. As demonstrated in our sub-acute study, NOD-scid mice
allowed for successful engraftment in 100% of transplanted
animals [19]. Furthermore, upon sacrifice stereological quantifi-
cation revealed 90% more hCNS-SCns than initially transplanted,
demonstrating that this model permits proliferation [30]. The
NOD-scid model has similar injury pathology to other mice strains
but allows for successful engraftment and therefore an ability to
assess the potential that human cell transplantation may have in
experimental models of SCI.
In the present study, we assessed survival and migration of
transplanted hCNS-SCns utilizing unbiased stereological quanti-
fication. All transplanted animals exhibited successful engraftment.
Furthermore, we found 187% more hCNS-SCns than initially
and human nuclei marker (J). (K–O) Human cytoplasm-positive cells SC121, green (M) also exhibit ß-tubulin III expression, red (L). DAPI counterstain,
blue (K). Arrows indicate a double-labeled cell. Merged confocal image, revealing hCNS-SCns expression of ß-tubulin III (N). Orthogonal view of
confocal image showing co-localization of ß-tubulin III and SC121 (O). (P–T) Few human cytoplasm cells SC121, red (Q) also expressed and the
astrocyte marker GFAP, green (R). DAPI counterstain, blue (P) Arrowhead indicates a non-astrocytic human cell. Co-localization was rare indicating
few hCNS-SCns exhibited astrocytic differentiation 16 weeks after transplantation (R). Orthogonal view of confocal image revealing co-localization of
GFAP and SC121 (S). Scale bars =20 mm and 10 mm in the bottom row.
doi:10.1371/journal.pone.0012272.g004
Figure 5. hCNS-SCns differentiation/fate quantification 16
weeks post-transplantation. Bar graph revealing quantification of
hCNS-SCns that expressed the proliferative marker Ki67, the immature
neural marker nestin, immature oligodendrocyte marker Olig2, the
mature oligodendrocyte marker APC-CC1, the neuronal marker ß-
tubulin III and the astrocytic marker GFAP expressed as percentages.
doi:10.1371/journal.pone.0012272.g005
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suggesting the transplanted cells are capable of limited prolifer-
ation. We also found long-distance migration from transplantation
sites. Notably the engrafted cells avoid the lesion but occupy the
spared tissue around the lesion. The cells migrated up to 8 mm
rostrally and 5 mm in the caudal direction. Interestingly, more
cells were found rostrally compared to caudally. This may be due
to the rostral cord still receiving connections from the brain
possibly contributing to a more trophic environment for
transplanted cells. Conversely, a recent study suggested that
regenerated sensory axons 6–8 months post-SCI remained
unmyelinated rostral to injury but were myelinated caudally
[61]. This may suggest that rostrally there is a need for
oligodendrocyte replacement for remyelination of spontaneously
regenerating or reorganizing sensory afferents. Therefore, the
rostral migration and oligodendrocyte differentiation of trans-
planted hCNS-SCns may be filling this niche. hCNS-SCns
transplanted into early chronic mouse SCI showed extensive
engraftment, long-distance migration, and limited proliferation.
hCNS-SCns differentiate into oligodendrocytes and neurons
Approximately 31% of hCNS-SCns remained nestin positive
suggesting that they remain undifferentiated, however of the cells
that differentiated the majority differentiated along the oligoden-
drocyte lineage expressing the immature Olig2 marker or the
mature APC-CC1 marker (41%) and nearly as many differentiated
into ß-tubulin III-positive neurons (38%). The sum of all
quantification markers was 128% suggesting there is overlap
between some of the markers. Nestin, in particular has been found
to co-localize with Olig2, b-tubulin III, and GFAP [62,63].
Additionally, there could potentially be some overlap between
Olig2 and APC-CC1 as cells are maturing along the oligoden-
drocyte lineage [64]. Interestingly, we observed increased
neuronal differentiation in animals transplanted at 30 dpi
compared to 9 dpi. hCNS-SCns may be responding to cues in
the host microenvironment that are altered between these two
time points resulting in the increased neuronal population. One of
the variables changing over time following SCI is the continued
influx of inflammatory cells. Our laboratory has recent data
suggesting a delayed wave of infiltrating neutrophils, macrophag-
es/microglia, and T-cells beginning about 21 dpi in Sprague-
Dawley rat spinal cords and continuing through 6 months post-
injury [65]. Post-mortem studies investigating human SCI tissue
have also revealed the presence of macrophages chronically [66].
The cell types that are present in the spinal cord microenviron-
ment at the time of cell transplantation and during differentiation
may influence the fate of transplanted cells. Further studies
investigating the factors that could contribute to increased
neuronal differentiation when transplanting in the chronic SCI
microenvironment are in progress. Furthermore, in contrast to
many other studies that report predominant astrocytic differenti-
ation after transplantation of NSCs into SCI models
[21,22,23,24,25,26] only about 8% of transplanted hCNS-SCns
differentiated into astrocytes. Several studies from our lab and
others have transplanted NSCs after SCI and also observed rare
astrocytic differentiation [13,19,58]. Interestingly, these studies
that observed rare astrocytic fate quantified at least 30% of
transplanted cells successfully engrafted, potentially suggesting an
immunological effect due to failure to prevent host immune
rejection may promote astrocytic differentiation. However, there
are many other variables that may promote astrocytic differenti-
ation of transplanted NSCs after SCI including the source of
transplanted NSCs, the culturing techniques, and cell preparation
Figure 6. Human cytoplasm co-localizes with paranodal protein CASPR. (A) Orthogonal view of a confocal image of SC121 (red), CASPR
(green) and DAPI counterstain (blue). The crosshair reveals co-localization of CASPR with SC121 and orthogonal projection. Arrows indicate additional
SC121-positive axons exhibiting compact CASPR-positive paranodes. Arrowheads indicate diffusely distributed CASPR. (B–E) High-power images
revealing examples of CASPR and SC121 co-localization. (B) High-power view of area in crosshair from (A). The two discrete CASPR-positive areas are
,4 mm apart suggesting they are two paranodal regions of a single node. (C) High-power view of another co-localized axon revealing two discrete
paranodal regions of a single node. (D, E) Additional high-power examples of SC121 co-localized with CASPR. Left scale bar =20 mm, right scale
bars =1 mm.
doi:10.1371/journal.pone.0012272.g006
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studies to elucidate the mechanisms resulting in astrocytic fate of
transplanted NSCs are necessary and ongoing in our laboratory.
Finally, a small percentage (2.9%) expressed Ki67 at the terminal
time-point indicating that there is some limited continuing
proliferation 16 weeks post-transplantation. However, no evidence
of excessive proliferation, clusters of proliferating cells, or tumor
formation was observed in any transplanted animals. NOD-scid
mice have previously been used as a host for transplanted induced
pluripotent cells and NSCs in the CNS as an assay for tumor
formation [16,17]. Tumor formation is much more likely to occur
in the absence of a rejection response therefore, NOD-scid mice
optimally allow for detection of tumor formation or abnormal
growth of transplanted stem cell populations. Further studies
investigating the kinetics of proliferation and migration at earlier
time points following transplantation are in progress.
hCNS-SCns integrate with the host
Because SC121-positive cells in the white matter predominantly
differentiated into oligodendrocytes, co-localization of the human
cytoplasmic marker SC121 with the paranodal protein CASPR
within the white matter of the spinal cord is suggestive of host
mouse axons remyelinated by hCNS-SCns that have differentiated
into oligodendrocytes. ß-tubulin III co-localization with SC121
was predominantly found within the gray matter and processes
rarely extended to the white matter. Despite SC121-positive axons
rarely extending into the white matter the possibility that some of
the observed co-localization with CASPR could represent
myelination of these fibers by the host, cannot be excluded.
Nonetheless, either case suggests that hCNS-SCns integrated with
the host in this early chronic transplant paradigm. The mechanism
of recovery is not known but integration of hCNS-SCns and
remyelination of host axons is one possibility. Additional studies
are necessary to further characterize the individual contributions
of oligodendroglial and neuronal differentiation of hCNS-SCns in
mediating locomotor recovery and establishing a mechanism of
recovery. Critically, the CASPR staining pattern revealed both
compact and diffuse CASPR, indicative of both normally
myelinated and dysmyelinated axons 20 weeks after SCI in
accordance with previous studies [43]. This suggests that
dysmyelinated areas remain in the chronic SCI environment in
NOD-scid mice, however the functional status of those axons
cannot be determined [42]. It will be important to further
characterize myelin pathology in the chronically injured spinal
cord, however, the co-localization of SC121 and CASPR in this
study suggest that it is possible to achieve hCNS-SCns-mediated
remyelination of at least a subset of these fibers after transplan-
tation in this early chronic SCI model which could contribute to
recovery of function.
hCNS-SCns do not affect lesion volume, spared tissue
volume, or glial scar area
While the presumptive strategy behind transplantation of stem
cell populations for SCI has been cell replacement via integration
as myelinating cells or new neurons, it is increasingly clear that
transplanted cells can have a variety of effects on the host
microenvironment. In the present study, we investigated lesion
volume, spared tissue volume, and glial scar area to determine
Figure 7. hCNS-SCns transplantation does not alter lesion volume, spared tissue volume, or glial scar area. (A) Representative spinal
cord stained for GFAP to stereologically quantify lesion volume, indicated by the blue outline, spared tissue volume, quantified 500 mm rostrally and
caudally from the lesion edges excluding the lesion, as depicted by the gray box, and the area of dense GFAP expression indicative of glial scarring
excluding the lesion, outlined in black. (B) Staining of human GFAP (SC123), indicating rare astrocytic differentiation localized primarily near the injury
site that did not exacerbate the glial scar. (C) Lesion volumes quantified using unbiased stereological probe Cavalieri Estimator show no significant
difference for any of the three groups (p$0.91 ANOVA). (D) Spared tissue volumes quantified using unbiased stereological probe Cavalieri Estimator
show no significant difference for any of the three groups (p$0.21 ANOVA). (E) Glial scar areas quantified using unbiased stereological probe
Cavalieri Estimator show no significant difference for any of the three groups (p$0.98 ANOVA). Scale bar =1000 mm.
doi:10.1371/journal.pone.0012272.g007
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these host parameters. Because we observed improved recovery,
we might expect the lesion size to be decreased [50,67].
Alternatively, we might have expected transplanted cells to
mediate recovery by increased sparing of white matter around
the lesion [68]. We also investigated glial scar area to determine
whether hCNS-SCns had reduced the size of the scar [49,50].
Alternatively, hCNS-SCns that differentiated into astrocytes could
have exacerbated the host glial scar. Stereological quantification of
these parameters revealed no differences between hCNS-SCns and
control groups. In a subsequent analysis of hCNS-SCns animals
transplanted sub-acutely [19], lesion volume, tissue sparing, glial
scarring, sprouting of host serotonergic fibers, and angiogenesis
were investigated utilizing unbiased stereological quantification
and no significant differences were detected between control and
hCNS-SCns transplanted animals on any of these parameters [30].
Taken together with the sub-acute study and the effect of human
cell ablation resulting in loss of locomotor recovery, these data
support the hypothesis that hCNS-SCns transplantation after SCI
mediates functional recovery by cellular integration with the host
and not by overt modification of the host microenvironment.
Chronic transplantation
Effective therapeutic NSC transplantation after SCI may only
be possible if the transplanted cell population is capable of
extensive migration, enabling cells to reach demyelinated and
dysmyelinated axons and/or spared circuitry above and below the
injury. Transplanted hCNS-SCns migrated multiple vertebral
levels away from the transplantation site. Since there was
significant oligodendroglial differentiation and we have previously
demonstrated hCNS-SCns are capable of remyelination in vivo,
one potential concern for chronic transplantation is whether
demyelinated/dysmyelinated axons persist chronically [42]. Mam-
malian SCI models have exhibited evidence for chronic demye-
lination/dysmyelination in surviving and regenerating axons
[43,61,69,70,71], suggesting remyelination as a viable therapeutic
target in chronic SCI. Additionally, studies examining naturally
occurring SCI in cats and dogs have found axons that are
demyelinated up to 12 weeks post-injury [72]. In human chronic
SCI tissue demyelinated and/or dysmyelinated fibers were
observed [73,74,75]. Additionally, myelination during critical
phases in the sub-acute and early chronic stages post-SCI could
enhance axon sparing [42,76], resulting in preservation of
function. Remyelination may be a viable target for chronic
transplantation, but may depend on timing in the acute to chronic
injury continuum and requires further exploration. One could
speculate that the preferential distribution of hCNS-SCns rostral
to the epicenter and predominant oligodendrocyte fate could
reflect a niche generated by the persistence of chronically
demyelinated/dysmyelinated spared axons.
Collectively, following both sub-acute and early chronic
transplantation we have shown that the predominant hCNS-SCns
differentiation is oligodendroglial and survival of hCNS-SCns is
required to sustain locomotor recovery, suggesting that oligoden-
drocyte integration with the host is likely a key mechanism of
recovery [19]. However, the mechanism is not known and
alternative pathways of hCNS-SCns-mediated repair must also
be considered. We observed 26% of hCNS-SCns differentiated
into neurons following sub-acute transplantation while 38%
differentiated into neurons following early chronic transplantation
suggesting a neuronal contribution [19]. Neuronal differentiation
of transplanted hCNS-SCns could promote restoration of
disrupted circuitry by formation of bridge or bypass connections.
Neuronal replacement may be particularly useful in cervical SCI,
where loss of motor neurons at the level of damage produce
specific deficits, e.g. decreased triceps control. Neuronal differen-
tiation could also provide trophic support to enhance neuropro-
tection and regeneration, or alter recruitment of endogenous
progenitors that could contribute to repair processes. Additionally,
NSCs can secrete a variety of neurotrophins in vitro and in vivo,
including GDNF and NGF [77,78]. Furthermore, human NSCs
that exhibited neuronal differentiation have been shown to secrete
GDNF following transplantation into traumatic brain injury [79].
Similarly, BDNF, GDNF, and NGF were present in higher
amounts in human NSC transplanted animals that exhibited
neuronal differentiation compared to controls following SCI [58].
Thus, despite predominant oligodendrocyte differentiation of
hCNS-SCns, contributions of neuronal differentiation to improved
locomotor recovery cannot be ruled out.
Previous studies have suggested SCI transplantation is more
effective sub-acutely rather than chronically [12,13,54,80].
However, our results suggest early chronic transplantation can
still be effective for successful engraftment, differentiation to non-
astrocytic lineages, and improvement of locomotor recovery.
However, it is important to note that 30 dpi is a relatively ‘‘early’’
chronic time point and greater delays should be investigated. A
relatively small proportion of the total SCI cases are new injuries
that could benefit from potential acute therapies. If chronic
therapies were developed, a much greater proportion of the SCI
population would have the potential to benefit.
Conclusion
The results of this study suggest that hCNS-SCns are capable of
surviving and differentiating when transplanted in an early chronic
injured microenvironment. The transplanted cells are not
restricted to an astrocytic lineage and differentiate predominantly
into oligodendrocytes and neurons. Furthermore, hCNS-SCns are
capable of enhancing locomotor recovery. Overall these data
suggest that hCNS-SCns transplantation may have potential as an
intervention for SCI beyond sub-acute time points, which is of
significant clinical relevance for the SCI population.
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